Reimbursement uncertainty
Test demand and cash collection depend on payer coverage, pricing, and denials.
- Scope
- Cologuard, Oncotype DX, Oncodetect
- Materiality
- high
Exact Sciences Corp
Exact Sciences Corp. develops and commercializes cancer screening and precision oncology tests used before, during, and after a cancer diagnosis. Its portfolio is anchored by Cologuard for colorectal cancer screening and Oncotype DX for treatment guidance, with newer products such as Cologuard Plus, Oncodetect, and Cancerguard expanding the pipeline.
−2,5 %
69,7 %
−6,4 %
+17,7 %
2.43
2.17
| % | |
|---|---|
| Screening | 78% Non-invasive cancer screening tests, primarily Cologuard and related screening offerings. |
| Precision Oncology | 22% Tumor and therapy-selection tests, led by Oncotype DX and related oncology diagnostics. |
Exact Sciences sells primarily to physicians, health systems, and other ordering providers that prescribe or manage...
- Primary care and screening providersprimary
They order Cologuard and related screening tests to expand colorectal cancer screening and close care gaps.
- Oncologists and cancer treatment teamsprimary
They order Oncotype DX and therapy-selection tests to guide treatment decisions after diagnosis.
- Payers and Medicareprimary
They reimburse tests and strongly influence adoption through coverage, pricing, and payment timing.
- International ordering providerssecondary
They buy Oncotype DX and other tests in markets such as Germany and Japan where provider adoption is growing.
- Patients in screening programssecondary
They are the end users of screening tests, especially where employer, provider, or care-gap outreach increases adherence.
The company is heavily U.S.-centric: about 95% of employees are located in the United States, and most testing and...
- •United States is the core market for screening and most testing volume
- •Germany has local Oncotype DX processing in Trier
- •Japan is an important international growth market for Oncotype DX
- •Phoenix, Arizona and Redwood City, California are key lab hubs
- •Marshfield, Wisconsin supports hereditary and germline testing
Exact Sciences is focused on expanding adoption of its current tests while launching new products that broaden its...
01
Grow adoption of current testsshort-term
Higher test volume improves revenue leverage and strengthens the installed provider base.
02
Launch and scale new productsshort-term
New products expand the company beyond its legacy screening franchise and diversify growth.
03
Build clinical evidence and reimbursementmedium-term
Coverage and clinical validation are essential for adoption in regulated diagnostics.
04
Expand access and patient adherencemedium-term
Screening volume depends on reaching more eligible patients and improving completion rates.
Exact Sciences faces reimbursement, regulatory, and execution risk because its products depend on payer coverage,...
Product development and regulatory execution
New diagnostics require clinical validation, FDA pathways, and evidence generation before scaling.
- Scope
- Cancerguard, blood-based CRC screening, SOAR trial
- Materiality
- high
Cybersecurity and data privacy
The company handles sensitive patient and payer data across internal systems and third parties.
- Scope
- ExactNexus platform, lab information systems, vendor network
- Materiality
- high
Competitive pressure
The market is rapidly evolving and competitors may launch alternative screening or oncology tests.
- Scope
- Screening and precision oncology
- Materiality
- high
International operating risk
Foreign markets add regulatory, labor, operational, and collection complexity.
- Scope
- Germany, Japan, broader international Oncotype DX business
- Materiality
- medium
Revenue recognition and transaction-price estimates
Can create prior-period adjustments and affect quarterly comparability
Amortization of acquired and licensed intangibles
Affects gross margin and operating profit
R&D and clinical study accruals
Can move operating expense trends and cash burn
Goodwill and intangible impairment
Could cause non-cash charges and reduce equity
: 28.4.2026